Advances in science set to transform dementia diagnosis and care

The UK is entering a new era of dementia care and innovation. A groundbreaking government-backed research challenge has been launched to accelerate earlier diagnosis and more effective treatment for people living with dementia using science and technology as the driving force for change.

Announced on 24 October 2025 by Science Minister Lord Vallance and Health Minister Dr Zubir Ahmed, the initiative forms part of the government’s R&D Missions Accelerator Programme, a £500 million multi-year strategy aimed at translating research into measurable health and societal outcomes.

With £5 million in initial funding, the Dementia Patient Flow R&I Challenge invites researchers and industry to develop practical technologies that will help diagnose dementia faster and more accurately, and improve long-term quality of life for millions of people across the UK.

In this blog, Dr Richard Dune explores what this means for the future of dementia care, research collaboration, and innovation in the UK’s health system. 

A national priority - Early, accurate diagnosis

More than one million people in the UK are currently living with dementia, a number projected to rise to 1.4 million by 2040. Despite growing awareness, diagnosis remains slow and inconsistent. Nearly half of those referred for assessment wait longer than 18 weeks for a formal diagnosis.

The new challenge sets an ambitious goal: by 2029, over 92% of patients should receive a diagnosis within 18 weeks of referral. To achieve this, researchers will explore new diagnostic pathways, from blood tests and saliva analysis to AI-driven digital assessments, designed to detect early indicators of dementia long before symptoms become visible.

Such breakthroughs could shift the focus from reactive care to proactive intervention, enabling early lifestyle changes, treatment plans, and access to clinical trials that slow disease progression and improve outcomes.

Lord Vallance underscored the importance of this ambition, saying:

“Few people in the UK will go through life untouched by the impact of dementia. We must therefore grasp the opportunities that science and technology offer in getting people the early and effective diagnosis they need to continue living fulfilled lives while reducing pressure on hospitals.”

Harnessing the power of AI and digital health

Emerging technologies are expected to play a crucial role in transforming dementia care. Researchers are exploring AI-powered home assistants that learn individual habits, suggest brain exercises, remind users about medication, and even help families stay connected through video calls.

These innovations promise to extend independence and dignity for people with dementia while reducing the burden on the NHS, where one in four acute hospital beds in England is currently occupied by someone living with dementia.

Dr Zubir Ahmed, Minister for Health, highlighted the programme’s potential impact:

“By harnessing the power of innovation to diagnose dementia faster and more accurately, we can ensure patients and their families get the support they need earlier, when it can make the greatest difference. Together, we will transform how we approach dementia care and give millions of people the chance of a better quality of life.”

Building on a foundation of world-class research

The challenge builds on existing national efforts, such as the Blood Biomarker Challenge, which aims to generate clinical and economic data to support the introduction of dementia blood tests within the NHS. These tests detect specific proteins linked to cognitive decline and could revolutionise early detection.

In parallel, UK Research and Innovation (UKRI) has announced £1.2 million in funding for two projects focused on digital cognitive assessments. Among them:

• Kneu Health, a University of Oxford spin-out, is developing smartphone-based testing that combines digital data with biological “biomarker” analysis

• The Food for the Brain Foundation is advancing a web-based assessment tool that evaluates key cognitive functions, such as memory and decision-making, for use both in clinics and at home.

Together, these projects aim to integrate seamlessly with NHS systems, giving healthcare professionals faster, richer diagnostic insights and patients more timely access to support.

A new frontier for dementia science

Leaders in neuroscience and dementia research have described the next five years as a potential turning point.

Professor Siddharthan Chandran, Director and CEO of the UK Dementia Research Institute, said:

“We’re now at an inflection point. The next five years will see a revolution in both therapeutics and diagnostics for dementia, and we’re already seeing the beginnings of that transformation today. Precise, early diagnosis isn’t just about giving people information, it’s about giving them agency, choice, and crucially, access to emerging clinical trials and treatments that offer real hope.”

He added that the UK’s unique collaboration between world-class universities, industry, and the NHS creates an unparalleled foundation for delivering such change.

Charities welcomed the announcement as a vital step toward addressing the long-standing gaps in dementia diagnosis and care.

Hilary Evans-Newton, Chief Executive at Alzheimer’s Research UK, commented:

“Right now, hundreds of thousands of people living with dementia miss out on a diagnosis and the answers, care and support that one can bring. That’s not just a crisis. It’s wrong. But innovations like blood tests, digital assessments and retinal scans are offering real hope, and they will soon be here.”

Similarly, Richard Oakley from Alzheimer’s Society called dementia “the leading cause of death in the UK” and praised the initiative for addressing “deep-rooted challenges in diagnosis” through innovation and collaboration.

Dr Hilda Hayo, Chief Admiral Nurse and CEO of Dementia UK, added:

“Early detection, combined with clear routes into the right care and support, means people can get help sooner. That timely support can transform the way families live with and manage dementia.”

Implications for the wider health and social care sector

For the health and social care workforce, these advances could reshape clinical pathways, workforce training, and service delivery. An earlier diagnosis will demand:

• Upskilling staff to interpret biomarker and digital test results

• Integrating technology such as AI tools into daily care routines

• Embedding data-driven care models that link primary care, community support, and specialist services.

As the Care Quality Commission (CQC) and Integrated Care Systems (ICSs) continue to emphasise person-centred, coordinated care, these scientific developments will strengthen the foundations for safer, more proactive dementia services.

From a workforce development perspective, early intervention also means carers, nurses, and allied professionals will require continuous professional development (CPD) in digital literacy, neurodegenerative care, and the use of assistive technologies, areas where structured, blended learning solutions will be essential.

Professor Lucy Chappell, Chief Scientific Adviser at the Department of Health and Social Care, emphasised the human impact behind this mission:

“Although we have made progress through science, collaboration, and community participation. It is essential that we continue to develop innovative tools to support those living with dementia. This announcement signifies a drive to invest in research to improve diagnosis, as we know what a difference a high-quality and timely diagnosis can make.”

A step toward a smarter, connected health system

The dementia R&D challenge symbolises a wider cultural and operational shift in UK healthcare toward prevention, precision, and partnership. By embedding AI, data, and diagnostic technologies within existing NHS systems, the government’s vision for a health service fit for the future is beginning to take shape.

For care providers, the implications go far beyond dementia. These models demonstrate how innovation, workforce training, and technology integration can jointly improve safety, efficiency, and patient outcomes across all regulated sectors.

About The Mandatory Training Group

The Mandatory Training Group is a leading UK provider of accredited health and social care training, compliance solutions, and workforce development programmes. Since 2016, we have supported thousands of organisations in building safer, more effective, and compliant services.

Through our train-the-trainer programmes, learning management system (LMS), and training management system (TMS), we help organisations deliver blended learning, manage compliance data, and achieve continuous improvement across all regulatory standards.

Our integrated ComplyPlus™ Regulatory Compliance Management Software enables care providers to streamline audits, monitor training, manage documents, and stay inspection-ready under frameworks such as the CQC Single Assessment Framework and Care Inspectorate Wales.

Reference

HM Government (2025) - Advances in science set to transform treatments for people living with dementia.